US 11,849,753 B2
Tobacco lozenge
Feng Gao, Midlothian, VA (US); Diane L. Gee, Chesterfield, VA (US); Shuzhong Zhuang, Glen Allen, VA (US); Phillip M. Hulan, Midlothian, VA (US); and William J. Burke, Nashville, TN (US)
Assigned to Altria Client Services LLC, Richmond, VA (US)
Filed by Altria Client Services LLC, Richmond, VA (US)
Filed on Feb. 10, 2021, as Appl. No. 17/172,557.
Application 16/370,020 is a division of application No. 14/506,003, filed on Oct. 3, 2014, granted, now 10,244,786, issued on Apr. 2, 2019.
Application 17/172,557 is a continuation of application No. 16/370,020, filed on Mar. 29, 2019, granted, now 10,925,309, issued on Feb. 23, 2021.
Claims priority of provisional application 61/886,399, filed on Oct. 3, 2013.
Prior Publication US 2021/0169127 A1, Jun. 10, 2021
Int. Cl. A24B 15/10 (2006.01); A24B 13/00 (2006.01); A24B 15/18 (2006.01)
CPC A24B 15/10 (2013.01) [A24B 13/00 (2013.01); A24B 15/18 (2013.01)] 14 Claims
OG exemplary drawing
 
1. An oral product comprising:
a body configured to be wholly receivable in an oral cavity, the body including,
a matrix including a soluble fiber in an amount greater than or equal to 95 weight percent of the body,
tobacco plant tissue, and
a medium chain triglyceride (MCT).